Severe COVID-associated lung injury is a major confounding factor of hospitalizations and death with no effective treatments. Here, we describe a non-classical fibrin clotting mechanism mediated by SARS-CoV-2 infected primary lung but not other susceptible epithelial cells. This infection-induced fibrin formation is observed in all variants of SARS-CoV-2 infections, and requires thrombin but is independent of tissue factor and other classical plasma coagulation factors. While prothrombin and fibrinogen levels are elevated in acute COVID BALF samples, fibrin clotting occurs only with the presence of viral infected but not uninfected lung epithelial cells. We suggest a viral-induced coagulation mechanism, in which prothrombin is activated by infection-induced transmembrane serine proteases, such as ST14 and TMPRSS11D, on NHBE cells. Our finding reveals the inefficiency of current plasma targeted anticoagulation therapy and suggests the need to develop a viral-induced ARDS animal model for treating respiratory airways with thrombin inhibitors.
Breast cancer is the most common cancer diagnosis worldwide accounting for 1 out of every 8 cancer diagnoses. The elevated expression of Thymidine Kinase 1 (TK1) is associated with more aggressive tumor grades, including breast cancer. Recent studies indicate that TK1 may be involved in cancer pathogenesis; however, its direct involvement in breast cancer has not been identified. Here, we evaluate potential pathogenic effects of elevated TK1 expression by comparing HCC 1806 to HCC 1806 TK1-knockdown cancer cells (L133). Transcriptomic profiles of HCC 1806 and L133 cells showed cell cycle progression, apoptosis, and invasion as potential pathogenic pathways affected by TK1 expression. Subsequent in-vitro studies confirmed differences between HCC 1806 and L133 cells in cell cycle phase progression, cell survival, and cell migration. Expression comparison of several factors involved in these pathogenic pathways between HCC 1806 and L133 cells identified p21 and AKT3 transcripts were significantly affected by TK1 expression. Creation of a protein-protein interaction map of TK1 and the pathogenic factors we evaluated predict that the majority of factors evaluated either directly or indirectly interact with TK1. Our findings argue that TK1 elevation directly increases HCC 1806 cell pathogenicity and is likely occurring by p21- and AKT3-mediated mechanisms to promote cell cycle arrest, cellular migration, and cellular survival.
Background/Objectives: Pathogenic mammarenaviruses cause severe hemorrhagic and neurologic disease in humans. Machupo virus (MACV), a New World (NW) mammarenavirus, causes Bolivian hemorrhagic fever in humans, and there are no approved vaccines. Methods: Here, we describe and compare the immunogenicity of three vaccines expressing the MACV glycoprotein complex (GPC) in C57BL/6 mice: a recombinant vesicular stomatitis virus (rVSV) and two different lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA (mRNA-LNP) vaccines. The first mRNA-LNP vaccine, designated MACV mRNA, expresses the full-length MACV GPC. The second mRNA-LNP vaccine, called MACV VLP mRNA, encodes MACV GPC with appended sequences that induce the budding of virus-like particles (VLPs) with MACV GPC on the surface. This is the first description of any mRNA-LNP vaccine for MACV and the first comparison of mRNA and rVSVs as vaccine candidates for MACV. Results: We find that two doses of either MACV mRNA or MACV VLP mRNA are required for the induction of robust humoral and cellular immune responses including total MACV GPC IgG, neutralizing antibodies, cross-reactive antibodies that bind the related Junín virus GPC, and MACV-specific T-cell responses. To further investigate vaccination strategies for MACV, we also evaluated a heterologous prime-boost regimen involving the MACV mRNA vaccine coupled with the rVSV-based MACV vaccine. We find that the highest levels of MACV GPC-specific IgG and neutralizing titers were achieved when heterologous mRNA and rVSV prime-boost regimens were employed. Conclusions: These results elucidate differences in the immune response to different vaccine platforms for MACV and can inform future vaccine development for NW arenaviruses.
Recombinant vesicular stomatitis virus (rVSV) is a powerful vaccine platform that elicits durable cellular and humoral immune responses. rVSV vaccines have successfully been used for various hemorrhagic fever-causing viruses. Here, we create and evaluate rVSV vaccines for Machupo virus (MACV), a highly pathogenic New World (NW) mammarenavirus that causes Bolivian hemorrhagic fever. VSV genome rearrangements impact attenuation of the viral vector and the immune response to the vaccine. Therefore, in this study, we directly compare the effect of altering the MACV glycoprotein complex (GPC) position in the VSV genome on humoral and cellular immune responses to vaccination by evaluating replication, antigen expression, and immunogenicity of rVSVs expressing MACV GPC in the first position of the genome (rVSV-MACV1) and in the traditional glycoprotein gene position (rVSV-MACV5). rVSV-MACV1 expresses higher levels of MACV GPC in infected cells and in virions, but the increased antigen does not translate to a more robust immune response. rVSV-MACV5 elicits higher levels of total IgG and neutralizing antibodies than rVSV-MACV1, but similar levels of MACV-specific T cells. To further investigate vaccine strategies for MACV and other NW arenaviruses such as Junín virus (JUNV), we evaluated the humoral immune response to sequential immunization with rVSVs expressing MACV and JUNV GPCs. The highest levels of MACV and JUNV reactive antibodies were achieved using an rVSV-MACV5 prime followed by rVSV-JUNV boost. The data from our study have implications for rVSV vaccine design and provide a foundation for the development of rVSV-vectored vaccines for MACV and other NW arenaviruses. IMPORTANCE: Machupo virus (MACV) is a highly pathogenic New World (NW) mammarenavirus that causes Bolivian hemorrhagic fever (BHF). Because of their high mortality rates, MACV and other NW arenaviruses represent a significant public health threat. However, no approved vaccines for MACV exist. Here, we describe recombinant vesicular stomatitis virus (rVSV) vaccines that express the MACV glycoprotein complex (GPC) in different positions of the VSV genome and characterize the humoral and cellular immune response to each. We also investigate sequential immunization with rVSVs expressing MACV GPC and a related NW arenaviral antigen, Junín virus GPC, in an effort to elicit broadly cross-reactive antibody responses. The conclusions from our study are twofold: data presented here provide further understanding of rVSV vaccine vectors and how genome rearrangements can be leveraged for vaccine development, and the results from our study may inform future vaccine development for MACV and other NW arenaviruses.